Last reviewed · How we verify
Fimasartan and Amlodipine
Fimasartan blocks angiotensin II receptors to lower blood pressure, while amlodipine relaxes blood vessels by blocking calcium channels, providing dual antihypertensive action.
Fimasartan blocks angiotensin II receptors to lower blood pressure, while amlodipine relaxes blood vessels by blocking calcium channels, providing dual antihypertensive action. Used for Hypertension.
At a glance
| Generic name | Fimasartan and Amlodipine |
|---|---|
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Drug class | Angiotensin II receptor blocker + Calcium channel blocker combination |
| Target | AT1 receptor (fimasartan); L-type calcium channel (amlodipine) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Fimasartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors, reducing vasoconstriction and aldosterone secretion. Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle cells, causing vasodilation. The combination provides complementary mechanisms for blood pressure reduction.
Approved indications
- Hypertension
Common side effects
- Dizziness
- Headache
- Peripheral edema
- Fatigue
- Hyperkalemia
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS/AML or FMS/AML/HCTZ
- Effect of Fimasartan on Extended RAS and Vascular Functions in Patients With Type 2 Diabetes and Hypertension (PHASE4)
- BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination (PHASE3)
- Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia (PHASE3)
- Combination of Fimasartan/Amlodipine/Hydrochlorothiazide in Healthy Male Subjects (PHASE1)
- Drug Interaction Study of Fimasartan/Amlodipine/Hydrochlorothiazide in Healthy Male Subjects (PHASE1)
- A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Amlodipine in Healthy Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fimasartan and Amlodipine CI brief — competitive landscape report
- Fimasartan and Amlodipine updates RSS · CI watch RSS
- Boryung Pharmaceutical Co., Ltd portfolio CI